Abstract:OBJECTIVE:To explore the clinical effect of L-ornithine L-aspartate (LOLA) granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase (G-GT) using a 24-week treatment course.METHODS:Two-hundred patients with chronic liver disease and above normal G-GT were given a 12-week course of LOLA granules (9 g/d) and then classified into the following three groups according to the change in serum Gamma-GT:group I:patients with Gamma-GT level returned to normal;group II:patients with serum Gamma-GT level that was reduced during the treatment; group III:patients with serum Gamma-GT level that did not decrease or that increased to a higher level than at start of treatment.After the 12-week treatment course, the patients in group I were divided into three subgroups for receipt of a control drug (compound glycyrrhizin, 50mg/d) or an additional 12-week course of Gamma-GT at a reduced dose (LOLA granules 3 g/d) or at the original dose; groups II and III were maintained on the initial dose for an additional 12 weeks.The groups were reassessed at the end of the second 12-week course (at the end of week 24 of the study's observation period).Count data were compared using the x2 test and measurement data were compared using the t-test.RESULTS:In group I, the serum Gamma-GT level was 90.9% at the end of the first 12-week course and dropped to a mean level of 52.2% for both of the subgroups that received the reduced and original dose after the additional 12 weeks of LOLA granules treatment; the difference from week 12 to week 24 was significant (x2=8.213, P less than 0.05).The 24-week change in serum Gamma-GT levels for the group I reduced and original dose subgroups vs.the control subgroup were also significantly different from those seen in groups II and III (P less than 0.05).The percentage of patients in group I who achieved normal level serum Gamma-GT after 24 weeks of treatment (78.6%) was significantly higher than that for the control group (vs.55.0%, x2=11.452, P less than 0.05).When the patients in group 1 who had received the 12 additional weeks of LOLA granules treatment were measured again at two weeks after the treatments had been discontinued (end of week 26), the percentage of patients with normal serum Gamma-GT level was 92.7%, with only three cases showing obviously abnormal levels; in contrast, the group I patients in the control group of the second 12-week study period had on 66.7% of patients with normal-level serum Gamma-GT.The difference in change between the treated groups (both reduced and original dose) and the control group was significant (x2=14.964, P less than 0.05).CONCLUSION:Patients whose serumGamma-GT levels returned to normal after receipt of LOLA granules for 12 weeks benefitted from an additional 12 weeks of consolidation treatment, and those given the treatment at the original dose benefitted most.Compared with the compound glycyrrhizin, LOLA granules provided a better maintenance of resolved Gamma-GT level.Therefore, the effect of LOLA appears to be reliable and stable as well as safe for clinical use.

Effect of L-ornithine L-aspartate Granules in Treating Chronic Liver Disease in Patients with High-Level Serum Gamma-Glutamyltransferase

[Aspartate-Ornithine Granules in the Treatment of Nonalcoholic Steatohepatitis: a Multiple-Dose Parallel Controlled Clinical Trial].

Serum amino acids changes in liver failure patients treated with non-bio-artificial liver support system

L‐ornithine‐l‐aspartate for Hepatic Encephalopathy in Patients with Cirrhosis: A Meta‐analysis of Randomized Controlled Trials

Efficacy of Ganzaoning Granules on the Patients with Nonalcoholic Steatohepatitis

Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy

Clinical Efficacy of L-ornithine-L-aspartate in the Management of Icteric Chronic Viral Hepatitis

Glutargin Versus Arginine for Hyperammonemia in Chronic Liver Diseases: A Randomized Controlled Trial

Effect of Glutamine on Serum Tumor Necrosis Factor-α and Interleukin-6 Levels in Patients with Hepatocirrhosis

Effect of Reduced Glutathione in Treatment of Non-alcoholic Fatty Liver Disease

Clinical Efficacy of Jiangzhiligan Granules Combined with Simvastatinin in Treatment of Non-alcoholic Fatty Liver Disease

Pegbelfermin for reducing transaminase levels in patients with non-alcoholic steatohepatitis: a dose-response meta-analysis of randomized controlled trials

Ganshuang granules alleviates non-alcoholic steatohepatitis in rats

Effect of L-ornithine-L-aspartate Combined with Lactulose in the Treatment of Patients with Hepatic Encephalopathy after Hepatic Cirrhosis

The effects of L-ornithin-L-aspartate on the quality of life in minimal hepatic encephalopathy

Randomised Clinical Trial:L-Ornithine-l-aspartate Reduces Significantly the Increase of Venous Ammonia Concentration after TIPSS

Meta analysis of efficacy of ornithine aspartate in the treatment of patients with fatty liver

Effect of Reduced Glutathione Combined with Metformin in the Treatment of Non-Alcoholic Fatty Liver Disease

Effects of diammonium glycyrrhizinate lipid ligand on glucolipid metabolism in nonalcoholic fatty liver disease

Clinical Observation of Ornithine Aspartate in Treatment of Hepatic Encephalopathy

Efficacy and Safety of Yinlan Yigan Granula in Treating Acute Icteric Viral Hepatitis